Results 131 to 140 of about 86,397 (161)
ABSTRACT Background Women who are pregnant are at increased risk of venous thromboembolism (VTE), which persists for up to 3 months following childbirth. Diabetes is known to increase the risk of serious cardiovascular outcomes. Objective To comprehensively review literature on the extent to which pre‐existing or gestational diabetes influences the ...
Molly Orrin+2 more
wiley +1 more source
Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy [PDF]
Borgeat, K A+4 more
core +1 more source
The cost of saving lives: Complications arising from prehospital tourniquet application
Abstract Background Uncontrolled hemorrhage is a leading cause of preventable death in trauma. Tourniquets (TQs) are commonly used to control bleeding in the prehospital setting, although their application is associated with risks. Therefore, this study aimed to identify complications arising from TQ use and to examine contributing risk factors ...
Mor Rittblat+5 more
wiley +1 more source
Position statement on the management of pregnancy in sickle cell disease
Sickle cell disease (SCD) is a hereditary haemoglobinopathy which causes multi‐organ dysfunction. Pregnancies in SCD are high risk with significant maternal and fetal morbidity and mortality, including vaso‐occlusive crises, thrombosis, anaemia, placental insufficiency, fetal growth restriction, preterm birth and medication effects. High level evidence
Mimi Yue+5 more
wiley +1 more source
Asymptomatic Hypertrophic Cardiomyopathy: Diagnosis and Therapy [PDF]
Fuentes, V L, Wilkie, L J
core +1 more source
ABSTRACT Background Systematic, multi‐disciplinary review of Severe Acute Maternal Morbidity (SAMM) can improve maternal outcomes. Routinely collected data, collated into the Queensland SAMM Dashboard, may facilitate local case review. We wanted to understand how SAMMs are reviewed locally and how centrally collated data supports review processes ...
Joanne Frost+2 more
wiley +1 more source
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller+13 more
wiley +1 more source
The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism [PDF]
Muir, K.W.
core +1 more source
Summary Introduction Unplanned hospital readmissions after surgery are substantial drivers of expenditure and bed occupancy within the healthcare system. As a result, any targeted interventions that reduce readmission in this population can have a significant impact on patient well‐being and the health budget. Methods We performed a large retrospective
Kirstie Evans+5 more
wiley +1 more source